0001209191-23-040572.txt : 20230703 0001209191-23-040572.hdr.sgml : 20230703 20230703162051 ACCESSION NUMBER: 0001209191-23-040572 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230701 FILED AS OF DATE: 20230703 DATE AS OF CHANGE: 20230703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEVANGIE DANIEL J CENTRAL INDEX KEY: 0001187406 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39387 FILM NUMBER: 231065476 MAIL ADDRESS: STREET 1: 85 SWANSON ROAD CITY: BOXBOROUGH STATE: MA ZIP: 01719 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Renalytix plc CENTRAL INDEX KEY: 0001811115 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: FINSGATE STREET 2: 5-7 CRANWOOD STREET CITY: LONDON STATE: X0 ZIP: EC1V 9EE BUSINESS PHONE: 44 29 2071 0570 MAIL ADDRESS: STREET 1: FINSGATE STREET 2: 5-7 CRANWOOD STREET CITY: LONDON STATE: X0 ZIP: EC1V 9EE FORMER COMPANY: FORMER CONFORMED NAME: Renalytix AI plc DATE OF NAME CHANGE: 20200430 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-07-01 0 0001811115 Renalytix plc RNLX 0001187406 LEVANGIE DANIEL J C/O RENALYTIX PLC FINSGATE, 5-7 CRANWOOD STREET LONDON X0 EC1V 9EE UNITED KINGDOM 1 0 0 0 Stock Option (right to buy) 2032-01-27 Ordinary Shares 40000 D One fourth (1/4th) of the shares subject to the option award vested on August 31, 2022, and one sixteenth (1/16th) of the shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service. The exercise price is 4.95 pounds sterling. The U.S. dollar equivalent of the exercise price is $6.25 using the Bank of England rate as of June 29, 2023 (1.00 pound sterling = $1.262). Exhibit List - Exhibit 24 - Power of Attorney /s/ Katie Kazem, Attorney-in-Fact 2023-07-03 EX-24 2 poa.txt POA DOCUMENT Exhibit 24 POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of James McCullough, O. James Sterling and Salim Hamir of Renalytix plc (the "Company") and Katie Kazem, Ibe Alozie, Arjan Ganji and Jason Minio of Cooley LLP, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC"), a Form ID and Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company; (2) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and (3) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion. The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or employed by or a partner at Cooley LLP or another law firm representing the Company, as applicable. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below. Date: 04/04/2023 /s/ Daniel J. Levangie Daniel J. Levangie